The success of copyright’s blockbuster initially sparked a boom for pharma, however recent shifts present a uncertain outlook for investors. Off-patent alternatives are eroding profits, and continued litigation add https://mathenqxp377483.blogars.com/39675242/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-investment